

[**Translation:** Please note that the following purports to be a translation from the Japanese original Notice of Resolution of the 107th Annual General Meeting of Shareholders for the business term ended December 31, 2017 of Chugai Pharmaceutical Co., Ltd. prepared for the convenience of shareholders outside Japan with voting rights. However, in the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Securities Code: 4519)

March 22, 2018

To the Shareholders:

**NOTICE OF RESOLUTION OF
THE 107th ANNUAL GENERAL MEETING OF SHAREHOLDERS**

We are pleased to announce that the matters below were reported and resolved at the 107th Annual General Meeting of Shareholders of Chugai Pharmaceutical Co., Ltd. held today (the “AGM”).

Yours very truly,

Tatsuro Kosaka
Representative Director, President and CEO
CHUGAI PHARMACEUTICAL CO., LTD.
(the “Company”)
1-1, Nihonbashi-Muromachi 2-chome Chuo-ku,
Tokyo

PARTICULARS

Matters Reported:

The Business Report for the Business Term (January 1, 2017 to December 31, 2017, the "Term"), Non-Consolidated Financial Statements for the Term, Consolidated Financial Statements for the Term, and the Report on the Results of Audit of the Consolidated Financial Statements conducted by the Accounting Auditor and the Audit & Supervisory Board.

The contents of the above were reported.

Matters Resolved:

First Proposal

Appropriation of Surplus

This item was approved and resolved as originally proposed. Appropriation of surplus for the end of the Term was decided to be JPY 33 per share of common stock of the Company, and JPY 18,043,606,086 in an aggregate amount.

Second Proposal

Election of five (5) Directors

This item was approved and resolved as originally proposed. Five (5) Directors, namely, Mr. Osamu Nagayama, Mr. Motoo Ueno, Mr. Tatsuhiro Kosaka, Dr. Yasuo Ikeda and Dr. Sophie Kornowski-Bonnet. Director Yasuo Ikeda satisfies the condition of Outside Director.

– End –

Directors and Corporate Auditors

Based on the resolution by the Board of Directors and the Audit & Supervisory Board which are held after the AGM, Directors and Audit & Supervisory Board Members of the Company are as follows:

Representative Director, Chairman	Osamu Nagayama	reelected	Director	Daniel O'Day	
Representative Director, Deputy Chairman	Motoo Ueno	reelected	Director	Sophie Kornowski- Bonnet	reelected
Representative Director, President	Tatsuro Kosaka	reelected	Full-time Audit & Supervisory Board Member	Shunji Yokoyama	
Outside Director	Yasuo Ikeda	reelected	Full-time Audit & Supervisory Board Member	Mamoru Togashi	
Outside Director	Masayuki Oku		Outside Audit & Supervisory Board Member	Hisashi Hara	
Outside Director	Yoichiro Ichimaru		Outside Audit & Supervisory Board Member	Takaaki Nimura	
Director	Christoph Franz				

New management structure of the Company, as of April 1, 2018, will be as follows:

Executive Vice President	Shinya Unno	Vice President	Tetsuya Yamaguchi
Executive Vice President	Yasushi Ito	Vice President	Toshihiko Komori
Executive Vice President	Osamu Okuda	Vice President	Hisanori Takanashi
Executive Vice President	Hisafumi Okabe	Vice President	Hiroshi Murata
Executive Vice President	Toshiaki Itagaki	Vice President	Shinji Hidaka
Senior Vice President	Susumu Kato	Vice President	Tsunanori Sato
Senior Vice President	Keiji Kono	Vice President	Kouichi Nishikawa
Senior Vice President	Junichi Ebihara	Vice President	Hiroyuki Matsumoto
Senior Vice President	Yoshiaki Ohashi	Vice President	Minoru Watanabe

PAYMENT OF DIVIDENDS

1. For shareholders designated a bank account to which the dividends are transferred:

Please confirm the enclosed “Dividend Account Statement” and “Confirmation of the Bank Account Details for Dividends”.

2. For shareholders not designated a bank account to which the dividends are transferred:

Please receive your dividends at your nearby office of Japan Post Bank or Japan Post Office by using the enclosed “Dividend Receipt” during the payment period (From March 23, 2018 to May 2, 2018).

3. For shareholders designated the system of dividend allotment to securities company accounts in proportion to the number of shares held:

Please inquire of your transfer account management institution (securities company, etc.).

– End –